Exploratory analysis of target concentration of lenvatinib in the treatment of hepatocellular carcinoma
Authors:
- 29 April 2021
- journal article
- research article
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 88 (2) , 281-288
Abstract
Purpose We aimed to evaluate exposure–toxicity/efficacy relationship of lenvatinib by determining its target trough concentration for patients with hepatocellular carcinoma (HCC). Methods In this retrospective, observational study, 28 HCC patients who had been treated with lenvatinib were enrolled between August 2018 and April 2020. We evaluated the association between the trough lenvatinib concentration and occurrence of grade ≥ 3 toxicities. Additionally, we estimated the association of the trough lenvatinib concentration with responder status (disease control; complete response, partial response, or stable disease), and progression-free survival (PFS). Results The mean trough lenvatinib concentration was significantly higher in the group with grade ≥ 3 toxicity (n = 15) than in the group with grade ≤ 2 toxicity (n = 13). Based on the receiver operating characteristic curve, the threshold values of the trough lenvatinib concentrations for predicting grade ≥ 3 toxicities and responder status were 71.4 ng/mL [area under the curve (AUC) 0.86, 95% confidence interval (CI) 0.71–1.00; p < 0.05] and 36.8 ng/mL (AUC 0.95, 95% CI 0.85–1.00; p < 0.05), respectively. Lenvatinib concentrations of 36.8–71.4 ng/mL resulted in longer PFS than concentrations < 36.8 ng/mL and ≥ 71.4 ng /mL [median 13.3 months (36.8–71.4 ng/mL) vs. 3.5 months (< 36.8 ng/mL) and 7.8 months (≥ 71.4 ng /mL), respectively]. Conclusions Considering these results, we propose that the target trough concentration of lenvatinib could be 36.8–71.4 ng/mL for maintaining disease control status and reducing grade ≥ 3 toxicity in the treatment of HCC.Keywords
This publication has 16 references indexed in Scilit:
- Imatinib, sunitinib and pazopanib: From flat‐fixed dosing towards a pharmacokinetically guided personalized doseBritish Journal of Clinical Pharmacology, 2019
- Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trialThe Lancet, 2018
- Practical Recommendations for Therapeutic Drug Monitoring of Kinase Inhibitors in OncologyClinical Pharmacology & Therapeutics, 2017
- Optimizing the dose in cancer patients treated with imatinib, sunitinib and pazopanibBritish Journal of Clinical Pharmacology, 2017
- Dose Finding of Lenvatinib in Subjects With Advanced Hepatocellular Carcinoma Based on Population Pharmacokinetic and Exposure-Response AnalysesThe Journal of Clinical Pharmacology, 2017
- Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinomaJournal of Gastroenterology, 2016
- Safety and Pharmacokinetics of Lenvatinib in Patients with Advanced Hepatocellular CarcinomaClinical Cancer Research, 2016
- Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinomaBritish Journal of Cancer, 2014
- Evidence for Therapeutic Drug Monitoring of Targeted Anticancer TherapiesJournal of Clinical Oncology, 2012
- Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemiaBlood, 2006